Imara M&A
ELVN-002 Had Favorable Mutant Coverage Compared to Tucatinib
Proliferation IC50 [nm]
Tucatinib ELVN-002
29
6
Proliferation IC50 Fold over
Tucatinib
ELVN-002
1
1
33
11
1
2
24
2
1
0.2
11
8
2
225
510
15
18
2
157
6
5
1
294
12
10
2
287
7
10
642
14
22
17
17
499
1104
88
41
38
13
3
34
43
1239
209
13
7
438
14
20
5
29
11
12
29
418
1284
7
64
11
3412
148
2524
21
>10000
>10000
HER2 Exon20
Insertion
Mutations
Common HER2
Point
Mutations
Ba/F3
HER2 Mutation
A775-G776-ins-C
A775-G776-ins-YVMA
A775-G776-ins-YVMS
A775-G776-ins-SVMA
A775-G776-ins-VVMA
A775-G776-ins-MMAY
A775-G776-ins-YVMA-R678Q
G776VC
wild-type
P95
G776-del-ins-IC
G776-del-ins-LC
G776-del-ins-VV
S310F
S310Y
R678Q
L755S
L755P
D769N
V773M
V777L
T798M
L869R
G776-V777-del-ins-CVC
G776-Del-ins-AVGC
V777-G778-ins-GC
P780-Y781-ins-GSP
L869R/T7981
V8421
BaF3 parental cell line
EGFR
3
3
ā w w
3
21
2
4
3
194
2
43
4
>10000
>10000
ā
15
1
1
0.4
0.4
1
14
44
0.3
2
0.4
118
5
87
1
>10000
>10000
1
2
3
7
2
5
2
2
1
1
0.5
0.5
1
1
3
0.3
1
1
32
0.4
7
1
>10000
>10000
}
YVMA: 71% E20IM NSCLC
VC: 11% E20IM NSCLC
22% HER2mut BRC
37View entire presentation